Transcription of JCOG0304 - トップページ：日本臨床腫瘍研究 ...
1 Japan Clinical Oncology Group (Bone and Soft Tissue Tumor Study Group) 14 H17- -006 23-A-20 JCOG0304 IFO/ADM phaseII Ifosfamide Adriamycin II ( ) 812-8582 3-1-1 879-5593 1-1 2003 3 8 JCOG 2003 12 8 1 2004 2 13 2 2004 3 11 JCOG 3 29 2005 2 3 1 2 14 2005 7 5 2 7 5 2005 8 18 3 8 18 2006 5 1 4 5 1 2007 5 18 1 5 18 2010 2 9 5 2 16 2013 5 29 6 6 1 IFO/ADM
2 PhaseII JCOG 0304 2/76 0. T2bN0M0 AJCC Grade2 3 FNCLCC PS 0-1 20 70 ADM + IFO 3 ADM 30mg/m2/day d 1-2 IFO 2g/m2/day d 1-53 1 ADM + IFO 2 - T2bN0M0 AJCC Grade2 3 FNCLCC PS 0-1 20 70 ADM + IFO 3 ADM 30mg/m2/day d 1-2 IFO 2g/m2/day d 1-53 1 ADM + IFO 2 - stageIII AJCC 6th edition T2bN0M0 Grade2 3 FNCLCC system ifosfamide (IFO)+adriamycin (ADM)
3 Primary endpoint : 2 Secondary endpoints 1 WHO 2 FNCLCC system Grade2 Grade3 3 1) 2) 10 4 28 X CT MRI T2bN0M0 AJCC 6th edition 5 6 7 8 9 10 20 70 11 PS ECOG 0-1 IFO/ADM phaseII JCOG 0304 3/76 12 13 14 14 7 3 1 3 3 4 2 1 ADM 30 mg/m2/day d1-2 (total 60 mg/m2) IFO 2g/m2/day d1-5 (total 10 g/m2) 3 1 75 4 2 10 14 CRF JCOG JCOG
